Kidney Effects of Empagliflozin in People with Type 1 Diabetes

David Z I Cherney; Petter Bjornstad; Bruce A Perkins; Julio Rosenstock; Dietmar Neubacher; Jan Marquard; Nima Soleymanlou

doi:10.2215/CJN.07700621

Kidney Effects of Empagliflozin in People with Type 1 Diabetes

Clin J Am Soc Nephrol. 2021 Nov;16(11):1715-1719. doi: 10.2215/CJN.07700621. Epub 2021 Sep 17.

Authors

David Z I Cherney¹, Petter Bjornstad², Bruce A Perkins³, Julio Rosenstock⁴, Dietmar Neubacher⁵, Jan Marquard⁶, Nima Soleymanlou⁶

Affiliations

¹ University Health Network, University of Toronto, Toronto, Ontario, Canada.
² University of Colorado Anschutz Medical Campus, Denver, Colorado.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and the Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
⁴ Dallas Diabetes Research Center at Medical City, Dallas, Texas.
⁵ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
⁶ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.

No abstract available

Keywords: clinical trial; diabetes; diabetes mellitus; diabetic kidney disease; empagliflozin; glomerular filtration rate; glucosides; kidney function decline; kidney protection; sodium-glucose co-transporter-2 inhibitor; type 1.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Albuminuria / urine
Benzhydryl Compounds / pharmacology*
Clinical Trials, Phase III as Topic
Controlled Clinical Trials as Topic
Creatinine / urine
Diabetes Mellitus, Type 1 / drug therapy*
Glomerular Filtration Rate / drug effects
Glucosides / pharmacology*
Hematocrit
Humans
Serum Albumin / drug effects
Sodium-Glucose Transporter 2 Inhibitors / pharmacology*
Uric Acid / blood

Substances

Benzhydryl Compounds
Glucosides
Serum Albumin
Sodium-Glucose Transporter 2 Inhibitors
Uric Acid
Creatinine
empagliflozin